在乳腺癌中HER2向抗体-药物结合毒性
Seohyuk Lee1,2, Adriana M Kahn1, Mariya Rozenblit1
1Department of Internal Medicine, Section of Medical Oncology, Yale University, New Haven, Connecticut, USA.
Cancer medicine
|December 9, 2025
概括
针对HER2的抗体-药物联合体 (ADC) 改善了乳腺癌的结果,但引起了毒性. 了解这些不良事件对于优化治疗疗效和患者安全至关重要.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 针对HER2的抗体-药物合物 (ADC) 代表了乳腺癌治疗的重大进展.
- 两种已批准的ADCs,trastuzumab deruxtecan和trastuzumab emtansine,被广泛使用,还有超过60种额外的候选药物正在开发中.
研究的目的:
- 审查目前关于与乳腺癌中HER2向ADCs相关的毒性数据.
- 要突出常见和严重的不良事件,以及剂量限制性毒性.
主要方法:
- 现有临床试验数据的叙述性审查.
- 专注于报道的特斯图祖马布 (emtansine) 和特斯图祖马布 (deruxtecan) 的副作用.
主要成果:
- 特拉斯图祖马布 (emtansine) 与表观症,疲劳,头痛,恶心和焦灼症有关.
- 特拉斯图祖马布德鲁克斯泰康通常会导致脱发,细胞衰竭,食欲下降,疲劳和胃肠道问题.
- 即使在低于最佳剂量时,也会发生不良事件,限制剂量升级以获得最大的疗效.
结论:
- 尽管具有临床益处,但HER2向的ADCs会导致各种系统性和器官特异性毒性.
- 这些不良事件,包括剂量限制性毒性,对最大限度地提高治疗疗效构成障碍.
- 需要进一步的研究,以减轻乳腺癌患者的ADC相关毒性.
更多相关视频
13:59High-Content Screening Assay for the Identification of Antibody-Dependent Cellular Cytotoxicity Modifying Compounds
Published on: August 18, 2023
2.7K
14:20Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
Published on: June 13, 2014
17.0K
相关概念视频
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
524
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
524
Combination Therapies and Personalized Medicine
5.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.9K
